Source-grounded facts extracted from Tarsus Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aziz Mottiwala resigned as Chief Commercial Officer at Tarsus Pharmaceuticals, Inc..
“On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.”
Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $145.4 million, net income $7.0 million, EPS $(0.16). Guidance reaffirmed.
“• Product sales, net: were $145.4 million compared to $78.3 million for the same period in 2025, driven by higher volume and improvements in the gross-to-net discount. • License fees and collaboration revenue: were $16.7 million related to a $15.0 million regulatory milestone achieved under the China Out-License and $1.7 million of required China withholding tax associated with this milestone. The milestone payment was recorded on a gross basis, which increased license fees and collaboration revenue by $1.7 million, with an equal offsetting amount recorded as foreign tax expense within provision for income taxes. There were no license fees and collaboration revenue in the same period in 2025. • Cost of sales: were $9.4 million compared to $5.2 million for the same period in 2025, due to manufacturing costs related to XDEMVY, the royalty Tarsus pays on net product sales, and amortization expense for the milestone payments made to our licensor, which is being amortized over its remaining”
Rosemary Crane resigned as Director at Tarsus Pharmaceuticals, Inc..
“On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025.”
Elizabeth Yeu resigned as Member of the Board of Directors at Tarsus Pharmaceuticals, Inc..
“In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the "Board") and from the committees of the Board on which she served, each effective as of the Effective Date.”
Elizabeth Yeu was appointed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..
“On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the "Effective Date").”
Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $27.6 million, net income $35.7 million, EPS $(1.01).
“million at the close, providing approximately $40 million net after the repayment of the previous facility First Quarter 2024 Financial Results • First quarter revenues were $27.6 million, driven primarily by $24.7 million in net product sales, and $2.9 million in license fees and collaboration revenue. • Cost of sales were $1.7 million, due to manufacturing”
Tarsus Pharmaceuticals, Inc. incurred term loan of $75 million with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent at 90-day average secured overnight financing rate ("SOFR"), plus a margin of 6.75% maturing April 19, 2029.
“The Loan Agreement provides for an initial term loan in the principal amount of $75 million (the "Tranche A Loan") which was funded on April 19, 2024 (the "Tranche A Closing Date").”
Tarsus Pharmaceuticals, Inc. entered into Loan Agreement with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent valued at initial term loan in the principal amount of $75 million (effective 2024-04-19).
“On April 19, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into an agreement with funds managed by Pharmakon Advisors LP, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders, and the guarantors party to such agreement (the “Loan Agreement”). The Loan Agreement provides for an initial term loan in the principal amount of $75 million”
Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC valued at expected to be approximately $93.7 million (effective 2024-02-29).
“On February 29, 2024, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 2,812,500 shares of the Company’s common stock, par value $0.0001 per share, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of its common stock (the “Offering”).”
Tarsus Pharmaceuticals, Inc. reported Full Year 2023 results: revenue $17.4 million.
“Total revenues were $17.4 million, driven primarily by $14.7 million in XDEMVY net product sales, representing approximately four months of sales following the launch in late August.”
Tarsus Pharmaceuticals, Inc. reported Fourth Quarter 2023 results: revenue $13.1 million, net income $(41.9 million), EPS $(1.31).
“Recent Business Achievements Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive”
Jose Trevejo departed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..
“On January 18, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company’s Chief Medical Officer (the “Transition”), effective as of January 18, 2024 (the “Transition Date”), and leaving his employment with the Company on February 17, 2024.”
Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $1.9 million, net income $(1.28), EPS $(1.28).
“Gland Disease ● TP-04 Topline Phase 2a (Galatea) Rosacea ● TP-05 Topline Phase 2a (Carpo) Lyme Disease Prevention ● Third Quarter 2023 Financial Results • Total revenues were $1.9 million, driven primarily by $1.7 million in net product sales, representing five weeks of sales following the launch of XDEMVY in late August. • Cost of sales were $0.4 million, due”
Tarsus Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $31.4 million.
“Second quarter net loss for 2023 was $31.4 million, compared to a net loss of $5.7 million for the same period in 2022”
Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters valued at approximately $93.6 million (effective 2023-08-01).
“On August 1, 2023, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 5,714,285 shares of the Company’s common stock, par value $0.0001 per share (the “Offering”).”
Tarsus Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
“Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Tarsus Pharmaceuticals, Inc. shareholders approved Election of three nominees as Class III directors at the 2023-06-22 meeting.
“The following nominees were elected to serve as Class III directors for a term that will continue until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Tarsus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.
“Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2023.”
Jeff Farrow was appointed as Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc..
“The Company also announced the appointment of Jeff Farrow as the Company’s Chief Financial Officer and Chief Strategy Officer, also effective as of the Transition Date.”
Leo Greenstein changed role as Chief Financial Officer at Tarsus Pharmaceuticals, Inc..
“On April 24, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Leo Greenstein would be leaving his role as the Company’s Chief Financial Officer (the “Transition”), effective as of April 24, 2023 (the “Transition Date”) and leaving his employment with the Company on June 15, 2023.”
Tarsus Pharmaceuticals, Inc. reported the full-year ended December 31, 2022 results: revenue $25.8 million.
“blepharitis ● TP-03 Topline Phase 2a (Ersa) Meibomian Gland Disease ● Full-Year 2022 Financial Results • Full year TP-03 out-license revenue for greater China territory was $25.8 million, compared to $57.0 million in 2021 • Full year net loss was $62.1 million, compared to $13.8 million in 2021 • Full year research and development expenses were $42.6 million,”
Tarsus Pharmaceuticals, Inc. amended First Amendment to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bank (effective 2023-01-05).
“On January 5, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”), Hercules Capital, Inc. (“Hercules”) and Silicon Valley Bank (“SVB” and together with Hercules, the “Lenders”) entered into a First Amendment to Loan and Security Agreement (the “First Amendment”) to amend that certain Loan and Security Agreement, by and between the Company and the Lenders, dated as of February 2, 2022”
Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..
“and Wendy Yarno, current member of the Board, as Lead Independent Director, each appointment effective as of December 2, 2022.”
Michael Ackermann resigned as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
“Michael Ackermann, the Chairperson of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of his resignation as the Chairperson and as a member of the Board and any committees of the Board, effective December 2, 2022.”
Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.
“to net loss of $15.7 million for the same period in 2021 • Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0, compared to $1.2 million for the same period in 2021 • Third quarter research and development expenses for 2022 were $10.9 million (inclusive of stock-based compensation of”
Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..
“Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director”
Bobak Azamian was appointed as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
“Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board”
Michael Ackermann changed role as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
“Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year”
Scott Morrison was appointed as Director at Tarsus Pharmaceuticals, Inc..
“expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.”
Elizabeth Yeu-Lin, M.D. was appointed as Director at Tarsus Pharmaceuticals, Inc..
“appointed Elizabeth Yeu-Lin, M.D. to the Board, effective immediately.”
Jason Tester resigned as Director at Tarsus Pharmaceuticals, Inc..
“Jason Tester, a member of the Company's Board and Chair of the Audit Committee of the Board, resigned from the Board and the Audit Committee of the Board”
Rosemary A. Crane was appointed as Chair of the Science and Technology Committee at Tarsus Pharmaceuticals, Inc..
“The Board appointed Ms. Crane to serve as Chair of the Science and Technology Committee”
Rosemary A. Crane was appointed as Chair of the Audit Committee at Tarsus Pharmaceuticals, Inc..
“the Board appointed Ms. Crane to serve as Chair of the Audit Committee of the Board.”
Rosemary A. Crane was appointed as Director at Tarsus Pharmaceuticals, Inc..
“appointed Rosemary A. Crane to the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.